Mereo BioPharma Group PLC MREO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/26/24 EDT
2.75quote price arrow up+0.01 (+0.36%)
Volume
2,109
Close
2.74quote price arrow down-0.07 (-2.49%)
Volume
560,441
52 week range
0.92 - 4.36
Loading...
  • Open2.81
  • Day High2.81
  • Day Low2.73
  • Prev Close2.81
  • 52 Week High4.36
  • 52 Week High Date02/05/24
  • 52 Week Low0.92
  • 52 Week Low Date05/31/23

Key Stats

  • Market Cap384.305M
  • Shares Out140.26M
  • 10 Day Average Volume0.91M
  • Dividend-
  • Dividend Yield-
  • Beta0.83
  • YTD % Change18.61

KEY STATS

  • Open2.81
  • Day High2.81
  • Day Low2.73
  • Prev Close2.81
  • 52 Week High4.36
  • 52 Week High Date02/05/24
  • 52 Week Low0.92
  • 52 Week Low Date05/31/23
  • Market Cap384.305M
  • Shares Out140.26M
  • 10 Day Average Volume0.91M
  • Dividend-
  • Dividend Yield-
  • Beta0.83
  • YTD % Change18.61

RATIOS/PROFITABILITY

  • EPS (TTM)-0.27
  • P/E (TTM)-10.33
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-38.756M
  • ROE (TTM)-40.95%
  • Revenue (TTM)8.919M
  • Gross Margin (TTM)73.75%
  • Net Margin (TTM)-365.71%
  • Debt To Equity (MRQ)16.13%

EVENTS

  • Earnings Date09/05/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Mereo BioPharma Group PLC

 

Profile

MORE
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two...
Michael Wyzga
Non-Executive Independent Chairman of the Board
Denise Scots-Knight Ph.D.
Chief Executive Officer, Director
Christine Fox
Chief Financial Officer
Charles Sermon
General Counsel, Company Secretary
Address
One Cavendish Place, Fourth Floor
London
W1G0QF
United Kingdom